View discussions in the
Daily Update Roundtable:
View Daily discussions highlighting
the most clinically relevant information
presented at IBCC4.
Click here to view the Webcasts
|
|
|
prIME
Oncology invites you to view Daily Update eNewsflashes highlighting the most clinically relevant information presented at the 4th Annual International Breast Cancer Conference (IBCC4) in Paris, France, 30 January through 1 February 2010.
Unmet needs in breast cancer: Which pathways will lead to solutions?
1 February 2010—During the final day of the 4th International Breast Cancer Conference (IBCC4)in Paris, presentations focused on the unmet needs of breast cancer in 2010.
Biology of triple-negative breast cancer
Plenary Session IV began with an elegant discussion given by Mark
Pegram, MD (University of Miami Miller School of Medicine, Miami,
United States), regarding the biology of triple-negative (estrogen
receptor (ER)–negative, progesterone receptor (PR)–negative, and HER2-negative) breast cancer...
Click here to read the complete eNewsflash
Early-stage breast cancer: Challenging conventional wisdom
31 January 2010—During the second day of the 4th International Breast Cancer Conference (IBCC4) in Paris, presentations focused on clinical updates and the role of histopathology and biology in the management of early-stage breast cancer.
Plenary Session II was introduced by Wolfgang Eiermann, MD (Munich and Red Cross Women Hospital, Munich, Germany), who emphasized that breast cancer is a heterogeneous disease comprising different molecular subtypes based on gene/protein expression profiling, and that individualization of the therapeutic decision-making process is necessary for improved outcomes in patients with breast cancer...
Click here to read the complete eNewsflash
Breast cancer biology: Is it transforming the treatment paradigm?
30 January 2010—During the first day of the 4th International Breast Cancer Conference in Paris, presentations focused on emerging portraits of breast cancer in 2010.
Martine Piccart-Gebhart, MD, PhD (Institute Jules Bordet, Brussels,
Belgium), introduced the program by stating there would be more of a
focus on biology with the ultimate goal of offering more tailored
therapies to breast cancer patients in daily clinical practice. With
this purpose in mind, 54 faculty from 14 countries have assembled to
address over 1100 delegates on a variety of topics, including
management of endocrine-responsive breast cancer, triple-negative
breast cancer, node-negative breast cancer, and individualizing
treatment approaches...
Click here to read the complete eNewsflash
|
|
